IVIG for Infection Prevention After CAR-T-Cell Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 10, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2028

Conditions
Hematologic Malignancies
Interventions
BIOLOGICAL

Immune Globulin Infusion (Human), 10% Solution

Given IV

BIOLOGICAL

Anti-CD19 CAR T Cells Preparation

Given CAR-T treatment

OTHER

Saline

Given IV

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

OTHER

Survey Administration

Ancillary studies

OTHER

Electronic Health Record Review

Ancillary studies

Trial Locations (5)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

33612

RECRUITING

Moffitt Cancer Center, Tampa

91010

RECRUITING

City of Hope Cancer Center, Duarte

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

02114

RECRUITING

Massachusetts General Hospital Cancer Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Takeda

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER